INmune Bio announced that the FDA granted Fast Track designation to its drug XPro1595 for treating early Alzheimer's disease, including mild cognitive impairment and mild dementia stages. This designation aims to speed up the development and review process due to the drug's potential to address neuroinflammation, a key factor in Alzheimer's progression. XPro1595 selectively targets soluble TNF to reduce brain inflammation while preserving immune functions. The company plans a Phase 2b/3 trial focusing on patients with biomarkers of inflammation to support regulatory approval.
Gentherm is showcasing its expansion into the home and office furniture markets at NeoCon 2026, introducing wellness experiences that integrate thermal and pneumatic comfort technologies. Building on decades of automotive and medical expertise, Genth...
Kyverna Therapeutics, a late-stage biopharmaceutical company developing cell therapies for autoimmune diseases, announced it will present at the H.C. Wainwright Nasdaq BioConnect Conference on May 19, 2026, and the Jefferies Global Healthcare Confere...
Xcel Brands announced that renowned dog behaviorist Cesar Millan will debut his new pet product collection, Trust, Respect, Love by Cesar Millan, on QVC in September 2026. The collection features high-quality pet essentials designed to enhance daily ...
Freshworks unveiled its AI Agent Studio within Freshservice, enabling organizations to deploy custom AI agents quickly to improve service operations. The platform integrates AI with enterprise tools like Microsoft Teams and HR systems, enhancing IT a...
Chemomab Therapeutics announced its Q1 2026 financial results and presented new clinical data showing nebokitug's promising effects in treating primary sclerosing cholangitis (PSC) and co-existing inflammatory bowel disease (IBD). The data revealed n...
